|
Corporate Presentation |
|
An Independent Blinded Review of Suspected Drug Induced Liver Injury In NASH Patients by a Panel of Pathologists and Hepatologists |
|
Efficacy, Safety, and Tolerability of Seladelpar in Patients With Compensated Liver Cirrhosis Due to Primary Biliary Cholangitis |
|
Treatment With Seladelpar in Patients With Primary Biliary Cholangitis and Prior Experience With Obeticholic Acid or Fibrates |
|
Effect of Seladelpar and CB-0406 Combination Therapy on Obesity, Liver Fibrosis and Steatosis in a Diet-Induced Obese Mouse Model of Biopsy-Confirmed NASH With Fibrosis |
